PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608724
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608724
Hypercalcemia Treatment Market, By Drug, By Severity, By Distribution Channel, By Geography
The hypercalcemia treatment market is estimated to be valued at USD 4.32 Bn in 2024 and is expected to reach USD 7.62 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 4.32 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 8.40% | 2031 Value Projection: | 7.62 Bn |
Hypercalcemia is a condition characterized by abnormally high levels of calcium in the blood. It occurs when the normal calcium regulatory system is disrupted and the parathyroid glands overproduce parathyroid hormone (PTH) or when bone resorption increases excessively. Some common causes of hypercalcemia include primary hyperparathyroidism, certain types of cancer, sarcoidosis, and excessive vitamin D or calcium supplementation. If left untreated, hypercalcemia can have severe consequences impacting multiple organs like kidneys, heart, and gastrointestinal tract. It may lead to dehydration, nausea, weakness, confusion, and in severe cases, coma. The current treatment landscape involves medications like bisphosphonates, calcitonin, and glucocorticoids that help reduce calcium resorption and excretion. However, the market still remains open for novel therapies with improved safety and tolerability profiles.
Market Dynamics:
The global hypercalcemia treatment market growth is driven by the rising prevalence of primary hyperparathyroidism, certain types of cancers, and increasing life expectancy. In addition, high calcium levels are frequently observed in patients with multiple myeloma and breast cancer. However, the market growth can be restrained by the availability of generic versions once patents expire on blockbuster drugs. The development of novel calcimimetics and therapies targeting calcium-sensing receptors provide lucrative opportunities. Regional expansions by key players and partnerships with local pharma companies will further aid commercialization of innovative treatment options.
Key Features of the Study:
This report provides in-depth analysis of the global hypercalcemia treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hypercalcemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Inc., Ascendis Pharma, Amgen Inc., Cipla, Hikma Pharmaceuticals, PLC, Apotex Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Sumitomo Pharma Co., Ltd., Alkem Labs, and Crinetics Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypercalcemia treatment market
Market Segmentation
- By Drug Insights (Revenue, USD Bn, 2019 - 2031)
- Bisphosphonates
- Calcimimetic Agents
- Calcitonin
- Glucocorticoids
- Denusomab
- Calcitonin
- Others
- By Severity Insights (Revenue, USD Bn, 2019 - 2031)
- Mild Hypercalcemia
- Moderate Hypercalcemia
- Severe Hypercalcemia
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer, Inc.
- Ascendis Pharma
- Amgen Inc.
- Cipla
- Hikma Pharmaceuticals, PLC
- Apotex Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkem Labs
- Crinetics Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hypercalcemia Treatment Market, By Drug
- Hypercalcemia Treatment Market, By Severity
- Hypercalcemia Treatment Market, By Distribution Channel
- Hypercalcemia Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
4. Hypercalcemia Treatment Market, By Drug, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Calcimimetic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Calcitonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Glucocorticoids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Denusomab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Calcitonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Hypercalcemia Treatment Market, By Severity, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Mild Hypercalcemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Moderate Hypercalcemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Severe Hypercalcemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Hypercalcemia Treatment Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Hypercalcemia Treatment Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug , 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug , 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug , 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug , 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug , 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug , 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ascendis Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals, PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alkem Labs
- Crinetics Pharmaceuticals, Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
